Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243424 · ClinicalTrials.gov registry record · Phase 3
CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,103
- Enrollment target
NCT01243424 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 6,103 participants.
The verdict
NCT01243424, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,103 participants
- Enrollment target
Study Summary
The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated cardiovascular risk receiving usual care, and compare outcome against glimepiride.
Interventions
- DRUG linagliptin
- DRUG glimepiride
- DRUG linagliptin placebo
- DRUG glimepiride placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,103 participants |
| Start Date | 2010-11-11 |
| Est. Completion | 2018-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01243424
The ClinicalTrials.gov registry entry for NCT01243424 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which linagliptin is the first listed.
NCT01243424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01243424 about?
NCT01243424 is a clinical study titled "CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes". The aim of the study is to investigate the longterm impact on cardiovascular morbidity and mortality, relevant efficacy parameters (e.g., glycaemic parameters) and safety (e.g., weight and hypoglycaemia) of treatment with linagliptin in patients with type 2 diabetes at elevated cardiovascular risk r...
What is the current status of trial NCT01243424?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,103 participants. The study started on 2010-11-11. Estimated completion is 2018-08-21.
What interventions are being tested in trial NCT01243424?
The interventions under investigation include: linagliptin (DRUG), glimepiride (DRUG), linagliptin placebo (DRUG), glimepiride placebo (DRUG).
Who is sponsoring clinical trial NCT01243424?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.